Option chain shows key data for Regulus Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS) Stock, Option Chain

Regulus Therapeutics

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Image26

News

Price Target

Markets

Analyst Ratings

Trading Ideas

BALL

BIRK

CHRW

CPRI

CRDO

ETSY

GTHX

RGLS

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

document-428338_1280

Movers

Regulus Therapeutics announced positive results from its study related to the treatment of autosomal dominant polycystic kidney disease (AKPD).

What&#39;s Going On With Regulus Therapeutics Stock Monday?

Penny Stocks

Small Cap

Intraday Update

AFRM

AUUD

BTTX

CCTG

FUTU

FWBI

GIII

HEAR

HGAS

HOOD

IMRX

KPLT

MDGL

MOMO

NOVA

PANL

PATH

PERF

PIXY

PRST

PUYI

RAYA

RCMT

RMBL

SPRB

SPRO

TCON

UNCY

WIMI

WOOF

Shares of  Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.

Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Regulus Therapeutics Inc

REGULUS RES INC by Regulus Resources, Inc.

Regulus Resources Inc

Regulus Therapeutics Announced Positive Clinical And Regulatory Updates From Its ADPKD Program, Says  Topline Data From An Interim Analysis Of Fourth Cohort Of Its Phase 1B Multiple-ascending Dose Clinical Trial Showed Continued Mechanistic Dose Response

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and maintains $10 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $10 Price Target

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 47.5 percent increase over losses of $(0.40) per share from the same period last year.

Earnings

Earnings Misses

Regulus Therapeutics Q3 EPS $(0.21) Misses $(0.17) Estimate

Biotech

General

Regulus Therapeutics Completes Enrollment Of Fourth Cohort In Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For Treatment Of Autosomal Dominant Polycystic Kidney Disease With 26 Patients Enrolled

Oppenheimer analyst Andreas Argyrides reiterates Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Outperform and maintains $7 price target.

Oppenheimer Reiterates Outperform on Regulus Therapeutics, Maintains $7 Price Target

Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 54.05 percent increase over losses of $(0.37) per share from the same period last year.

Regulus Therapeutics Q2 EPS $(0.17) Misses $(0.13) Estimate

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and raises the price target from $11 to $28.

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Raises Price Target to $28

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>JP Morgan cut the price target for Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) from $84 to $78. JP Morgan analyst Ranjan Sharma downgraded the stock from Overweight to Neutral. Sea shares gained 0.6% to close at $75.89 on Monday. <a href="https://www.benzinga.com/quote/SE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley raised the price target for Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) from $44 to $58. Morgan Stanley analyst Edouard Aubin maintained an Equal-Weight rating. Birkenstock shares fell 2.8% to close at $59.78 on Monday. <a href="https://www.benzinga.com/quote/BIRK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen boosted Credo Technology Group Holding Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) price target from $24 to $35. TD Cowen analyst Matt Ramsay upgraded the stock from Hold to Buy. Credo Technology shares fell 0.7% to close at $27.29 on Monday. <a href="https://www.benzinga.com/quote/CRDO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS boosted the price target for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from $76 to $82. UBS analyst Roger Boyd upgraded the stock from Sell to Neutral. Cloudflare shares rose 0.9% to close at $78.60 on Monday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut G1 Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) price target from $12 to $6. Needham analyst Gil Blum maintained a Buy rating. G1 Therapeutics shares fell 10.5% to close at $2.22 on Monday. <a href="https://www.benzinga.com/quotTHXe/G/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo lowered Capri Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) price target from $57 to $43. Wells Fargo analyst Ike Boruchow upgraded the stock from Equal-Weight to Overweight. Capri shares gained 0.7% to close at $31.51 on Monday. <a href="https://www.benzinga.com/quote/CPRI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Evercore ISI Group raised the price target for C.H. Robinson Worldwide, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRW#NASDAQ">CHRW</a>) from $82 to $99. Evercore ISI Group analyst Jonathan Chappell upgraded the stock from In-Line to Outperform. C.H. Robinson shares gained 2% to close at $88.49 on Monday. <a href="https://www.benzinga.com/quote/CHRW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut Etsy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) price target from $58 to $56. Wells Fargo analyst Ken Gawrelski maintained an Underweight rating. Etsy shares fell 0.4% to close at $59.95 on Monday. <a href="https://www.benzinga.com/quote/ETSY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) price target from $9 to $10. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Regulus Therapeutics shares fell 18.3% to close at $2.05 on Monday. <a href="https://www.benzinga.com/quote/RGLS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities boosted Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) price target from $67 to $76. Truist Securities analyst Michael Roxland upgraded the stock from Hold to Buy. Ball shares rose 1.5% to close at $61.58 on Monday. <a href="https://www.benzinga.com/quote/BALL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/06/39471224/stocks-to-watch-on-tuesday-boeing-fedex-and-more">Stocks To Watch On Tuesday: Boeing, FedEx And More</a>

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy and raises the price target from $9 to $10.

HC Wainwright & Co. Maintains Buy on Regulus Therapeutics, Raises Price Target to $10

Regulus Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares were initially trading higher Monday before pulling back and turning negative after the company announced topline results from its study related to the treatment of autosomal dominant polycystic <a href="https://www.benzinga.com/quote/RGLS/analyst-ratings">kidney disease (AKPD)</a>.
What Happened: The results from the Phase 1B MAD clinical trial of RGLS8429 which Regulus announced Monday before the market opened, demonstrating a decrease in htTKV and an increase in PC1 and PC2. PC1 and PC2 are proteins known to inversely correlate with disease severity.
&#8220;We are pleased to see the consistent mechanistic response and reduction in htTKV at the 3mg/kg dose level of RGLS8429,&#8221; said president and head of research and development Preston Klassen, M.D.
Additionally, the treatment was well tolerated across participants.
Related Link: <a href="https://www.benzinga.com/markets/asia/24/06/39456640/yidu-finds-good-medicine-in-regulatory-nod-for-its-ai">Yidu Finds Good Medicine In Regulatory Nod For Its AI</a>
RGLS Price Action: Regulus Therapeutics shares are down 20.3% at $2.00 at the time of writing per <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: 428338 from Pixabay.

What's Going On With Regulus Therapeutics Stock Monday?

WIIM

Regulus Therapeutics shares are trading lower after the company announced results in the Phase 1b Study for ADPKD treatment. The stock initially traded higher, but it has since reversed.

ALNY: 14% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39453602">Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Phase 3 study of vutrisiran and that it met the primary endpoints and demonstrated statistically significant improvements across all secondary endpoints.</a>
ALT: 20% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39453064">Altimmune shares are trading higher after the company announced that it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association&#39;s 84th Scientific Sessions.</a>
RGLS: 41% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39453355">Regulus Therapeutics shares are trading higher after the company announced topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.</a>

ALNY

Market-Moving News for June 24th

Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the &quot;Company&quot; or &quot;Regulus&quot;), today announced positive topline results from the third cohort of patients in its Phase&nbsp;1b&nbsp;MAD study of RGLS8429 for the treatment of ADPKD.
<a href="https://mma.prnewswire.com/media/370141/regulus_logo_finalnew_Logo.html" target="_blank"><img alt="Regulus Therapeutics Inc. Logo" src="https://mma.prnewswire.com/media/370141/regulus_logo_finalnew_Logo.jpg" /></a>
The Phase&nbsp;1b&nbsp;MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. The study is evaluating RGLS8429 treatment across three different weight-based dose levels and one fixed dose level, including measuring changes in urinary polycystins 1 and 2 (PC1 and PC2), htTKV, cyst architecture, and overall kidney function. PC1 and PC2 are the protein products of the PKD1 and PKD2 genes and have been shown to inversely correlate with disease severity. Enrollment in the fourth cohort, which will include up to 30 patients, has been initiated and patients will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months. In addition to PC1 and PC2 and safety, imaging biomarkers will also be evaluated.
In the third cohort, 16 subjects were randomized 3:1 to receive either 3 mg/kg of RGLS8429 or placebo every other week for three months.
<ul>
<li>RGLS8429 was well tolerated with no safety concerns</li>
<li>Continued evidence of a mechanistic dose response was observed following completion of 3 mg/kg dose level based on urinary PC1 and PC2</li>
<li>3 mg/kg demonstrated more consistent increases in PC1 and PC2 across patients compared to earlier cohorts</li>
<li>Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo</li>
<li>Exploratory MRI imaging analysis suggested RGLS8429 reduced htTKV at 3 mg/kg after 3 months of dosing</li>
<li>70%&nbsp;of subjects demonstrated reductions in htTKV following completion of 3 mg/kg dose level</li>
</ul>
&quot;We are pleased to see the consistent mechanistic response and reduction in htTKV at the 3mg/kg dose level of RGLS8429 along with an appropriate safety and tolerability profile,&quot; said&nbsp;Preston Klassen, M.D., President and Head of Research &amp; Development. &nbsp;&quot;These data support our ongoing and final 300 mg fixed dose cohort in this Phase&nbsp;1b&nbsp;trial. We believe the data from this study will form the basis for a potentially pivotal Phase 2/3 study of RGLS8429 under an Accelerated Approval regulatory pathway to be discussed with the FDA.&quot;
&quot;Building on the positive results from our first two cohorts, these cohort 3 data, particularly the reduction in htTKV seen in the majority of patients, further strengthen our conviction in RGLS8429&#39;s ability to potentially address the underlying, genetic cause of ADPKD,&quot; said&nbsp;Jay Hagan, CEO of Regulus Therapeutics. &quot;We anticipate requesting an End-of-Phase 1 meeting with the FDA in the&nbsp;fourth quarter&nbsp;of this year and look forward to providing a data update from the open-label fourth and final cohort of the Phase&nbsp;1b&nbsp;MAD study by year-end.&quot;

Regulus Therapeutics Announces Results in Phase 1b Study for ADPKD Treatment

Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000&#xAE; Index and the Russell 2000&#xAE; Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th.

Regulus Therapeutics Announces Expected Addition To The Russell 3000 And Russell 2000 Indexes

Jones Trading analyst Catherine Novack initiates coverage on Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) with a Buy rating and announces Price Target of $8.

Initiation

Jones Trading Initiates Coverage On Regulus Therapeutics with Buy Rating, Announces Price Target of $8

Health Care

Contracts

TECH

Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease

Press Releases

Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes

Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences

Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates

Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences

Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429)

Comments

Regulus Therapeutics

Regulus Therapeutics (RGLS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga